Skip to main navigation
Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Advisory Boards
    • Milestones
    • Collaborations
  • Pathologies
    • The Inner Ear
    • Tinnitus
    • Hearing loss
    • Vertigo
    • Antipsychotic side effects
  • Product Candidates
    • Pipeline
    • AM-125
    • AM-201
    • AM-301
    • Sonsuvi® (AM-111)
    • Keyzilen® (AM-101)
    • Intratympanic administration
  • Newsroom
    • News
    • Presentations
    • Publications
    • Links
  • Investors

      Investor Relations

      • Investor Relations
      • Events and Presentations
      • Corporate Governance
      • Financial Information
      • Press Releases
      • Stock Information
      • Major Shareholders
      • Investor FAQs
      • Investor Contact
      • Information Request
      • Email Alerts
      • Information related to Reverse Split

 

 

Breadcrumb

Home /  Investors /  SEC Filings /  SC 13G/A / 

SEC Filing Details

Document Details

Form
SC 13G/A
Filing Date
Feb 12, 2021
Document Date
Feb 12, 2021
Form Description
An amendment to the SC 13G filing
Filing Group
Other
Company
Auris Medical Holding Ltd.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Investors

    Investors

    • Investor Relations
    • Events and Presentations
    • Corporate Governance
    • Financial Information
    • Press Releases
    • Stock Information
    • Major Shareholders
    • Investor FAQs
    • Investor Contact
    • Information Request
    • Email Alerts
    • Information related to Reverse Split

Investor Toolkit

  • Print Page
  • RSS Feeds

Careers   |    Contacts

Copyright © Auris Medical 2021